Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid CancersLori J. Wirth, Maria E. Cabanillas, Eric J. Sherman et al.|New England Journal of Medicine|2020Cited by 766
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced CancersBranimir I. Šikić, Sukhmani K. Padda, Maureen Howard et al.|Journal of Clinical Oncology|2019Cited by 590
2‐Methoxyestradiol, a Promising Anticancer AgentNehal J. Lakhani, William D. Figg, Mohamadi Sarkar et al.|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2003Cited by 276
ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain MetastasesPriya Kumthekar, Nuhad K. Ibrahim, Shou‐Ching Tang et al.|Clinical Cancer Research|2020Cited by 242
Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade GliomasHoward A. Fine, Craig B. Borkowf, Patrick Y. Wen et al.|Journal of Clinical Oncology|2003Cited by 174